» Articles » PMID: 30618654

Advances in Parkinson's Disease: 200 Years Later

Overview
Journal Front Neuroanat
Date 2019 Jan 9
PMID 30618654
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

When James Parkinson described the classical symptoms of the disease he could hardly foresee the evolution of our understanding over the next two hundred years. Nowadays, Parkinson's disease is considered a complex multifactorial disease in which genetic factors, either causative or susceptibility variants, unknown environmental cues, and the potential interaction of both could ultimately trigger the pathology. Noteworthy advances have been made in different fields from the clinical phenotype to the decoding of some potential neuropathological features, among which are the fields of genetics, drug discovery or biomaterials for drug delivery, which, though recent in origin, have evolved swiftly to become the basis of research into the disease today. In this review, we highlight some of the key advances in the field over the past two centuries and discuss the current challenges focusing on exciting new research developments likely to come in the next few years. Also, the importance of pre-motor symptoms and early diagnosis in the search for more effective therapeutic options is discussed.

Citing Articles

Chemosensory Impairments and Their Impact on Nutrition in Parkinson's Disease: A Narrative Literature Review.

Alia S, Andrenelli E, Di Paolo A, Membrino V, Mazzanti L, Capecci M Nutrients. 2025; 17(4).

PMID: 40004999 PMC: 11858080. DOI: 10.3390/nu17040671.


Patient-centered brain transcriptomic and multimodal imaging determinants of clinical progression, physical activity, and treatment needs in Parkinson's disease.

Adewale Q, Khan A, Lin S, Baumeister T, Zeighami Y, Carbonell F NPJ Parkinsons Dis. 2025; 11(1):29.

PMID: 39952947 PMC: 11828931. DOI: 10.1038/s41531-025-00878-4.


Mitochondrial Dysfunction in Parkinson's Disease: A Contribution to Cognitive Impairment?.

Scorziello A, Sirabella R, Sisalli M, Tufano M, Giaccio L, DApolito E Int J Mol Sci. 2024; 25(21).

PMID: 39519043 PMC: 11546611. DOI: 10.3390/ijms252111490.


Motor deficits and brain pathology in the Parkinson's disease mouse model hA53Ttg.

Breznik L, Daurer M, Rabl R, Loeffler T, Etxeberria-Rekalde E, Neddens J Front Neurosci. 2024; 18:1462041.

PMID: 39371610 PMC: 11450652. DOI: 10.3389/fnins.2024.1462041.


Enhancements in Parkinson's Disease Management: Leveraging Levodopa Optimization and Surgical Breakthroughs.

Sharma R, Kour A, Dewangan H Curr Drug Targets. 2024; 26(1):17-32.

PMID: 39350551 DOI: 10.2174/0113894501319817240919103802.


References
1.
Pastor P, Ezquerra M, Munoz E, Marti M, Blesa R, Tolosa E . Significant association between the tau gene A0/A0 genotype and Parkinson's disease. Ann Neurol. 2000; 47(2):242-5. View

2.
Kosel S, Grasbon-Frodl E, Mautsch U, Egensperger R, von Eitzen U, Frishman D . Novel mutations of mitochondrial complex I in pathologically proven Parkinson disease. Neurogenetics. 2000; 1(3):197-204. DOI: 10.1007/s100480050029. View

3.
Golbe L, Lazzarini A, Spychala J, Johnson W, Stenroos E, Mark M . The tau A0 allele in Parkinson's disease. Mov Disord. 2001; 16(3):442-7. DOI: 10.1002/mds.1087. View

4.
Boeve B, Silber M, Ferman T, Lucas J, Parisi J . Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord. 2001; 16(4):622-30. DOI: 10.1002/mds.1120. View

5.
Parkinson J . An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002; 14(2):223-36; discussion 222. DOI: 10.1176/jnp.14.2.223. View